Abbott Laboratories (ABT)
$103.72
0.00 (0.00%)
ABT Stock Quote Delayed 30 Minutes
10 Pharma Blue Chips to Buy
There are a number of great companies in pharma if you know where to look.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
181.61B
PE Ratio
32.31
EPS
3.21
Volume (Avg. Vol.)
1,834
Day's Range
-
52-Week Range
$89.67 - $121.64
Dividend & Yield
$2.04 (1.97%)
ABT Stock Predictions, Articles, and Abbott Laboratories News
Roche’s Hostile Bid for Illumina Could Reach $60 Per Share
Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done.
Are Pharma’s ‘Good Old Days’ Gone Forever?
You bet they are: Patent losses, a higher bar for FDA approvals, and slew of smaller, nimbler rivals have reshaped the industry.
8 Pharma Stocks in Good Health
The health care sector is a field that will continue to grow as Baby Boomers get old and retire. These eight companies will be at the center of this trend.
3 Dividend Stocks to Buy and Hold Forever
Each of these stocks has a rich dividend history -- with increases year after year -- making them good choices for both regular and retirement portfolios.
FDA, Insurers Demand Tests for New Drugs
Pressure on pharmaceutical companies for evidence that their drugs work is fueling a surge in the global market for "companion diagnostics."
Hard-to-Find Bargain Stock Buys
The stock market's brisk fourth-quarter rally (which has since begun to stall) has made bargains more difficult to find, but here's a few.
RIMM Completes a Week of Gloomy Outlooks — Friday’s IP Market Recap
Research In Motion joined Intel, Best Buy and First Solar in forecasting leaner times ahead. Here's a look at RIM, as well as other big news from this week.
FedEx Flies, Discover Dives — Thursday’s IP Market Recap
Both beat earnings estimates, but then went separate ways.
Covidien Follows Abbott With a Pharma Spin-Off
Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?
7 Feel-Good Pharma Stocks to Buy
Medicine is something few people can afford to go without during times of recession, making these pharma companies good sources of stability.
Abbott Labs Spinoff Looks Like the Right Move
Shareholders would likely be better served by the company's prescription drug business standing alone. Here's why.
3 Dividend Stocks to Ride the Rally
Investors who are nervous about diving back into the stock market should just dip their toes in the water. Here are three reliable dividend stocks to consider.
5 Dividend Aristocrats to Buy for 2012
These "aristocrats" have paid dividends for over two decades.
Get in Position for the Next Mega-Bull Market
There's plenty of turbulence ahead, but plentiful times will return. Follow this prudent investment strategy to set yourself up for an eventual bull market.
Top 6 Stocks for November
Investors can use the high volatility to buy this month’s picks at reasonable prices. Here are six that stand out.
Amgen Bids for a Return to Favor
Amgen's (AMGN) third-quarter earnings, budget management and full-year outlook turn positive, boosting the company's market prospects.
Top 6 Dividend Picks for November
These low-risk dividend investments are capable of delivering income and strong returns in the year ahead.
5 Potential Acquisition Targets in Medical Device Stocks
Big-name med-tech companies are looking to branch out in a $300 billion market. Here are five potential targets that could be swallowed up soon.
Market’s Recent Strength Nudges 3 Stocks Into Breakouts
These three companies have paired good corporate news with an overall positive market and, as a result, their stocks are challenging their trading ceilings.
